| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
ej
í
* Lautenberg Center for General and Tumor Immunology, Hebrew University-Hadassah Medical School, Jerusalem, Israel;
Department of Obstetrics and Gynecology, Hadassah University Hospital, Mount Scopus, Jerusalem, Israel; and
Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Praha, Czech Republic
The nonclassical class I MHC molecule HLA-G is selectively expressed on extravillous cytotrophoblast cells at the maternal-fetal interface during pregnancy. HLA-G can inhibit the killing mediated by NK cells via interaction with the inhibitory NK cell receptor, leukocyte Ig-like receptor-1 (LIR-1). Comparison of the sequence of the HLA-G molecule to other class I MHC proteins revealed two unique cysteine residues located in positions 42 and 147. Mutating these cysteine residues resulted in a dramatic decrease in LIR-1 Ig binding. Accordingly, the mutated HLA-G transfectants were less effective in the inhibition of NK killing and RBL/LIR-1 induced serotonin release. Immunoprecipitation experiments demonstrated the involvement of the cysteine residues in the formation of HLA-G protein oligomers on the cell surface. The cysteine residue located at position 42 is shown to be critical for the expression of such complexes. These oligomers, unique among the class I MHC proteins, probably bind to LIR-1 with increased avidity, resulting in an enhanced inhibitory function of LIR-1 and an impaired killing function of NK cells.
This article has been cited by other articles:
|
|
 |
|
  S. Liang, V. Ristich, H. Arase, J. Dausset, E. D. Carosella, and A. Horuzsko Modulation of dendritic cell differentiation by HLA-G and ILT4 requires the IL-6--STAT3 signaling pathway PNAS, June 17, 2008; 105(24): 8357 - 8362. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. D. Carosella, B. Favier, N. Rouas-Freiss, P. Moreau, and J. LeMaoult Beyond the increasing complexity of the immunomodulatory HLA-G molecule Blood, May 15, 2008; 111(10): 4862 - 4870. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Allen Response to Gauster et al. Rheumatology, May 1, 2007; 46(5): 893 - 894. [Full Text] [PDF]
|
|
|
|
|
|
T. Raine, D. Brown, P. Bowness, J. S. Hill Gaston, A. Moffett, J. Trowsdale, and R. L. Allen Consistent patterns of expression of HLA class I free heavy chains in healthy individuals and raised expression in spondyloarthropathy patients point to physiological and pathological roles Rheumatology, November 1, 2006; 45(11): 1338 - 1344. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Shiroishi, K. Kuroki, L. Rasubala, K. Tsumoto, I. Kumagai, E. Kurimoto, K. Kato, D. Kohda, and K. Maenaka Structural basis for recognition of the nonclassical MHC molecule HLA-G by the leukocyte Ig-like receptor B2 (LILRB2/LIR2/ILT4/CD85d) PNAS, October 31, 2006; 103(44): 16412 - 16417. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Fons, S. Chabot, J. E. Cartwright, F. Lenfant, F. L'Faqihi, J. Giustiniani, J.-P. Herault, G. Gueguen, F. Bono, P. Savi, et al. Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells Blood, October 15, 2006; 108(8): 2608 - 2615. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Shiroishi, K. Kuroki, T. Ose, L. Rasubala, I. Shiratori, H. Arase, K. Tsumoto, I. Kumagai, D. Kohda, and K. Maenaka Efficient Leukocyte Ig-like Receptor Signaling and Crystal Structure of Disulfide-linked HLA-G Dimer J. Biol. Chem., April 14, 2006; 281(15): 10439 - 10447. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Le Rond, C. Azema, I. Krawice-Radanne, A. Durrbach, C. Guettier, E. D. Carosella, and N. Rouas-Freiss Evidence to Support the Role of HLA-G5 in Allograft Acceptance through Induction of Immunosuppressive/ Regulatory T Cells. J. Immunol., March 1, 2006; 176(5): 3266 - 3276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Gonen-Gross, H. Achdout, T. I. Arnon, R. Gazit, N. Stern, V. Horejsi, D. Goldman-Wohl, S. Yagel, and O. Mandelboim The CD85J/Leukocyte Inhibitory Receptor-1 Distinguishes between Conformed and {beta}2-Microglobulin-Free HLA-G Molecules J. Immunol., October 15, 2005; 175(8): 4866 - 4874. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Stern, G. Markel, T. I. Arnon, R. Gruda, H. Wong, S. D. Gray-Owen, and O. Mandelboim Carcinoembryonic Antigen (CEA) Inhibits NK Killing via Interaction with CEA-Related Cell Adhesion Molecule 1 J. Immunol., June 1, 2005; 174(11): 6692 - 6701. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Le Friec, F. Gros, Y. Sebti, V. Guilloux, C. Pangault, R. Fauchet, and L. Amiot Capacity of myeloid and plasmacytoid dendritic cells especially at mature stage to express and secrete HLA-G molecules J. Leukoc. Biol., December 1, 2004; 76(6): 1125 - 1133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Hiby, J. J. Walker, K. M. O'Shaughnessy, C. W.G. Redman, M. Carrington, J. Trowsdale, and A. Moffett Combinations of Maternal KIR and Fetal HLA-C Genes Influence the Risk of Preeclampsia and Reproductive Success J. Exp. Med., October 18, 2004; 200(8): 957 - 965. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kollnberger, L. A. Bird, M. Roddis, C. Hacquard-Bouder, H. Kubagawa, H. C. Bodmer, M. Breban, A. J. McMichael, and P. Bowness HLA-B27 Heavy Chain Homodimers Are Expressed in HLA-B27 Transgenic Rodent Models of Spondyloarthritis and Are Ligands for Paired Ig-Like Receptors J. Immunol., August 1, 2004; 173(3): 1699 - 1710. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
